Changes in the European Union definition for endocrine disruptors
How many molecules remain a cause for concern? The example of crop protection products used in agriculture in France in the six last decades
Bibliographic Data
| ID | 22070236 |
|---|---|
| Authors | Cloé Roger (Lyon 1 Université), Adèle Paul (Lyon 1 Université), Emmanuel Fort (0000-0003-1419-9914, Lyon 1 Université), Céline Lamouroux (0000-0001-9674-1070, Lyon 1 Université), Areejit Samal (0000-0002-6796-9604, Homi Bhabha National Institute), Johan Spinosi (Santé Publique France), Barbara Charbotel (0000-0001-8805-6225, Lyon 1 Université, corresponding author) |
| Year | 2024 |
| Volume | 11 |
| Pages | 1343047-1343047 |
| Publication date | 2024-01-16 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Public Health (JOURNAL) |
| Journal identifiers | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Publisher | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2023.1343047 |
| PMID | 38292391 |
| OpenAlex | W4390910743 |
| Language | EN |
| References cited | 14 |
Background: The endocrine-disrupting effects of phytopharmaceutical active substances (PAS) on human health are a public health concern. The CIPATOX-PE database, created in 2018, listed the PAS authorized in France between 1961 and 2014 presenting endocrine-disrupting effects for humans according to data from official international organizations. Since the creation of CIPATOX-PE, European regulations have changed, and new initiatives identifying substances with endocrine-disrupting effects have been implemented and new PAS have been licensed. Objectives: The study aimed to update the CIPATOX-PE database by considering new 2018 European endocrine-disrupting effect identification criteria as well as the new PAS authorized on the market in France since 2015. Methods: The endocrine-disrupting effect assessment of PAS from five international governmental and non-governmental initiatives was reviewed, and levels of evidence were retained by these initiatives for eighteen endocrine target organs. Results: The synthesis of the identified endocrine-disrupting effects allowed to assign an endocrine-disrupting effect level of concern for 241 PAS among 980 authorized in France between 1961 and 2021. Thus, according to the updated CIPATOX-PE data, 44 PAS (18.3%) had an endocrine-disrupting effect classified as "high concern," 133 PAS (55.2%) "concern," and 64 PAS (26.6%) "unknown effect" in the current state of knowledge. In the study, 42 PAS with an endocrine-disrupting effect of "high concern" are similarly classified in CIPATOX-PE-2018 and 2021, and 2 new PAS were identified as having an endocrine-disrupting effect of "high concern" in the update, and both were previously classified with an endocrine-disrupting effect of "concern" in CIPATOX-PE-2018. Finally, a PAS was identified as having an endocrine-disrupting effect of "high concern" in CIPATOX-PE-2018 but is now classified as a PAS not investigated for endocrine-disrupting effects in CIPATOX-PE-2021. The endocrine target organs associated with the largest number of PAS with an endocrine-disrupting effect of "high concern" is the reproductive system with 31 PAS. This is followed by the thyroid with 25 PAS and the hypothalamic-pituitary axis (excluding the gonadotropic axis) with 5 PAS. Discussion: The proposed endocrine-disrupting effect indicator, which is not a regulatory classification, can be used as an epidemiological tool for occupational risks and surveillance
Business · Endocrine system · Environmental health · European union · Hormone · International trade · Political science · Agricultural safety and regulations · Effects and risks of endocrine disrupting chemicals · Medicine · Pesticide Residue Analysis and Safety · Endocrinology
| Citation velocity | historical |
|---|---|
| Highly cited | No |